Equities

Polarean Imaging PLC

Polarean Imaging PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)1.33
  • Today's Change-0.075 / -5.36%
  • Shares traded20.57m
  • 1 Year change-94.95%
  • Beta0.3255
Data delayed at least 20 minutes, as of Jun 14 2024 16:28 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Polarean Imaging PLC is a medical-imaging technology company, with an investigational drug-device combination product for magnetic resonance imaging (MRI). The Company and its subsidiary company operate as investigational drug-device combination companies operating in the high-resolution medical imaging research space. The Company develops equipment that enables existing MRI systems to achieve an improved level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream. The Company’s technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. It operates in Canada, Germany, United Kingdom and United States. The Company’s subsidiary is Polarean, Inc.

  • Revenue in GBP (TTM)269.12k
  • Net income in GBP-11.31m
  • Incorporated2016
  • Employees28.00
  • Location
    Polarean Imaging PLC2500 Meridian Pkwy #175DURHAM 27713United StatesUSA
  • Phone+1 (919) 206-7900
  • Fax+1 (919) 206-7901
  • Websitehttps://polarean.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Signal Advance Inc631.00-184.97k3.63m0.00--2.63--5,755.84-0.0056-0.00560.000020.03810.0001-------3.9114.53-4.0815.13-----29,331.2573.68----0.00------11.34------
Luxxu Group Ltd3.44m-4.30m3.81m56.00--0.4264--1.11-0.079-0.0790.06330.16420.23560.59830.8658608,983.80-29.42-33.26-33.95-35.127.795.23-124.85-126.114.40-4.040.2545---50.83-21.6118.06------
Insplorion AB213.06k-1.70m4.01m12.00--2.06--18.84-2.52-2.520.18711.090.0797-2.105.58218,538.50-63.67-29.27-74.89-34.48238.58260.36-799.37-791.031.63--0.0409---2.70-4.88-14.18--12.48--
Hanvey Group Holdings Ltd18.74m-1.99m4.10m110.00--2.17--0.2186-0.1196-0.11961.120.11320.82845.049.311,687,882.00-8.89-6.91-23.71-19.1423.3324.18-10.74-7.460.9283-1.070.8947---31.880.3471-85.65---39.81--
Mantex AB512.24k-1.25m4.28m6.00--2.03--8.36-0.0813-0.08130.03320.11180.21680.248742.991,138,403.00-52.99-63.52-59.16-74.9179.0663.55-244.40-303.494.68-72.410.1288--373.294.58-7.49------
Biolidics Ltd158.46k-1.69m4.77m15.00------30.12-0.0045-0.00450.0004-0.00230.0991.191.1118,133.33-105.67-51.21---69.1957.7241.13-1,068.02-165.860.239-31.02-----47.170.73273.46------
Polarean Imaging PLC269.12k-11.31m5.55m28.00--0.3421--20.62-0.0453-0.04530.00110.0390.01530.11340.19719,611.50-64.22-59.80-72.25-68.3839.6559.23-4,201.18-574.074.66--0.0225---12.86-3.540.7877--30.60--
Memphasys Ltd24.56k-2.36m5.77m24.00--1.37--234.86-0.0046-0.00460.000050.00590.00330.2732-----31.43-16.26-46.11-19.7344.48---9,600.13-21,518.040.1368-11.780.456---43.39---63.43--8.14--
Aurora Solar Technologies Inc6.13m-989.94k6.38m----1.88--1.04-0.0098-0.00980.05050.02660.91081.517.98---14.71-82.57-22.77-106.4452.4143.93-16.15-135.081.22-39.660.0665----17.05-5.49--13.30--
Telesis Bio Inc19.42m-37.15m6.58m137.00------0.3388-28.31-28.3114.8012.940.32313.275.58179,802.90-59.34---67.10--60.43---183.66--3.08-35.890.2015--0.2697---1.14------
Precipio Inc12.46m-3.86m6.77m51.00--0.6539--0.5428-3.73-3.7311.608.930.877317.8517.93310,039.20-27.20-44.98-34.82-58.6839.1428.80-31.00-118.070.6201-350.950.0278--61.4639.6252.04--5.37--
Medclair AB3.00m-285.13k6.84m14.00--1.8350.362.28-0.0435-0.04350.51340.60350.63181.394.452,859,714.00-6.00-11.20-7.34-12.9563.1369.51-9.50-26.940.9761-11.650.0053--60.1352.1444.27--24.59--
Bio-View Ltd7.36m81.12k7.08m--77.161.1615.180.96120.00320.00320.25680.21630.82892.335.48--0.91323.451.234.5761.4858.711.104.202.15--0.1138--19.296.58-34.75--8.77--
Data as of Jun 14 2024. Currency figures normalised to Polarean Imaging PLC's reporting currency: UK Pound GBX

Institutional shareholders

8.17%Per cent of shares held by top holders
HolderShares% Held
Yarra Investment Management Ltd.as of 28 Feb 202310.65m2.59%
Chelverton Asset Management Ltd.as of 28 Feb 20239.96m2.43%
Canaccord Genuity Wealth Ltd.as of 28 Feb 20238.34m2.03%
Unicorn Asset Management Ltd.as of 31 May 20243.18m0.77%
Aviva Investors Global Services Ltd.as of 30 Apr 2024614.76k0.15%
Premier Fund Managers Ltd.as of 30 Nov 2023509.69k0.12%
Thornbridge Investment Management LLPas of 31 Oct 2022322.81k0.08%
More ▼
Data from 30 Sep 2023 - 31 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.